Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

BACKGROUND: Enzalutamide is an antiandrogen used to treat both metastatic and nonmetastatic prostate cancer. Here we present results from a phase 2 trial designed to determine the safety, tolerability, and efficacy of adding enzalutamide to standard androgen deprivation therapy with radiation therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Shee, Kevin, de la Calle, Claire M., Chang, Albert J., Wong, Anthony C., Feng, Felix Y., Gottschalk, Alexander R., Carroll, Peter R., Nguyen, Hao G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Scientific Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280039/
https://www.ncbi.nlm.nih.gov/pubmed/35847550
http://dx.doi.org/10.1016/j.adro.2022.100941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280039/
https://www.ncbi.nlm.nih.gov/pubmed/35847550
http://dx.doi.org/10.1016/j.adro.2022.100941

Ejemplares similares